Pantoprazole

Generic Name
Pantoprazole
Brand Names
Protonix, Somac Control, Tecta, Pantozol Control, Controloc Control
Drug Type
Small Molecule
Chemical Formula
C16H15F2N3O4S
CAS Number
102625-70-7
Unique Ingredient Identifier
D8TST4O562
Background

Pantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome. It can also be...

Indication

Pantoprazole Injection:

Treatment of gastroesophageal reflux disease associated with a history of erosive esophagitis
...

Associated Conditions
Erosive Esophagitis, GERD With Erosive Esophagitis, Gastro-esophageal Reflux Disease (GERD), Healing, Heartburn, Helicobacter Pylori Infection, Stress Ulcers, Zollinger-Ellison Syndrome, Conditions where a reduction of gastric acid secretion is required, Pathological hypersecretory conditions
Associated Therapies
-
Clinical Trials
Related News

Efficacy of Pantoprazole 20/40 mg Once Daily (od) in Patients Older Than 12 Years Who Have Gastrointestinal Symptoms of Reflux Disease

First Posted Date
2009-01-27
Last Posted Date
2012-05-08
Lead Sponsor
Nycomed
Target Recruit Count
4188
Registration Number
NCT00829738
Locations
🇩🇪

Nycomed Deutschland GmbH, Überlingen, Germany

Incretin Effect and Use After Clinical Islet Transplantation

Phase 2
Completed
Conditions
Type 1 Diabetes
Interventions
Drug: Pantoprazole
Drug: Sitagliptin
First Posted Date
2008-10-08
Last Posted Date
2015-06-18
Lead Sponsor
University of Alberta
Target Recruit Count
8
Registration Number
NCT00768651
Locations
🇨🇦

University of Alberta - Clinical Islet Transplant Program, Edmonton, Alberta, Canada

Intravenous (IV) Pantoprazole for Gastroesophageal Reflux Disease (GERD) in Neonates and Infants

Phase 1
Completed
Conditions
Gastroesophageal Reflux
Interventions
Drug: pantoprazole
First Posted Date
2008-09-01
Last Posted Date
2015-12-03
Lead Sponsor
University of Louisville
Target Recruit Count
24
Registration Number
NCT00744419
Locations
🇺🇸

University of Louisville Research Foundation, Inc/KCPCRU, Louisville, Kentucky, United States

Intravenous Proton Pump Inhibitor for Peptic Ulcer Bleeding

Phase 4
Completed
Conditions
Peptic Ulcer Hemorrhage
Interventions
Drug: pantoprazole
First Posted Date
2008-08-11
Last Posted Date
2009-04-07
Lead Sponsor
Lotung Poh-Ai Hospital
Target Recruit Count
120
Registration Number
NCT00731601
Locations
🇨🇳

Lotung Poh-Ai hospital, Yilan, Taiwan

Effectiveness of the Eradication of Helicobacter Pylori and an Inhibitor of Pump With Proton Versus Control

First Posted Date
2008-07-14
Last Posted Date
2015-04-21
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Registration Number
NCT00713947
Locations
🇫🇷

Hotel Dieu Hospital, Paris, France

Influence of Pantoprazole on Human Myocardial Contractility at Patients With Congestive Heart Failure

Phase 3
Withdrawn
Conditions
Congestive Heart Failure
Interventions
Drug: Pantoprazole
First Posted Date
2008-06-18
Last Posted Date
2014-02-11
Lead Sponsor
Johann Wolfgang Goethe University Hospital
Registration Number
NCT00699361
Locations
🇩🇪

Johann Wolfgang Goethe University Hospitals, Department of Cardiology, Frankfurt am Main, Germany

A Comparative Study of Proton-pump Inhibitor Tests for Chinese Reflux Patients in Relation to the CYP2C19 Genotypes

Not Applicable
Completed
Conditions
GERD
Interventions
Drug: rabeprazole
Drug: pantoprazole
First Posted Date
2008-05-20
Last Posted Date
2013-12-11
Lead Sponsor
National Taiwan University Hospital
Target Recruit Count
178
Registration Number
NCT00681005

Effect of Pantoprazole 40mg Daily vs Placebo on Power Spectral Analysis of the Sleep EEG of Patients With GERD.

First Posted Date
2008-05-07
Last Posted Date
2010-08-19
Lead Sponsor
Southern Arizona VA Health Care System
Target Recruit Count
40
Registration Number
NCT00674245
Locations
🇺🇸

Southern Arizona VA Health Care System, Tucson, Arizona, United States

A Randomized, Open-Label, Comparative 3-Way Treatment Crossover Study of 24-Hour Intragastric pH Profile of Once Daily Oral Administration of Esomeprazole 40mg, Lansoprazole 30mg, and Pantoprazole 40mg at Steady State in NSAID-Using Patients

First Posted Date
2008-02-28
Last Posted Date
2008-02-28
Lead Sponsor
AstraZeneca
Target Recruit Count
100
Registration Number
NCT00625274

Placebo-Controlled Crossover Study for the Investigation of the Effect of Pantoprazole on Cardiac Contractility

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Pantoprazole
Drug: Placebo
First Posted Date
2008-01-24
Last Posted Date
2009-03-24
Lead Sponsor
Herzzentrum Goettingen
Target Recruit Count
20
Registration Number
NCT00600041
Locations
🇩🇪

Dept. of Cardiology and Pneumology; Herzzentrum Goettingen, Goettingen, Germany

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy